title: Patient-derived skeletal dysplasia induced pluripotent stem cells display abnormal chondrogenic marker expression and regulation by BMP2 and TGFβ1.
abstract: Skeletal dysplasias (SDs) are caused by abnormal chondrogenesis during cartilage growth plate differentiation. To study early stages of aberrant cartilage formation in vitro, we generated the first induced pluripotent stem cells (iPSCs) from fibroblasts of an SD patient with a lethal form of metatropic dysplasia, caused by a dominant mutation (I604M) in the calcium channel gene TRPV4. When micromasses were grown in chondrogenic differentiation conditions and compared with control iPSCs, mutant TRPV4-iPSCs showed significantly (P<0.05) decreased expression by quantitative real-time polymerase chain reaction of COL2A1 (IIA and IIB forms), SOX9, Aggrecan, COL10A1, and RUNX2, all of which are cartilage growth plate markers. We found that stimulation with BMP2, but not TGFβ1, up-regulated COL2A1 (IIA and IIB) and SOX9 gene expression, only in control iPSCs. COL2A1 (Collagen II) expression data were confirmed at the protein level by western blot and immunofluorescence microscopy. TRPV4-iPSCs showed only focal areas of Alcian blue stain for proteoglycans, while in control iPSCs the stain was seen throughout the micromass sample. Similar staining patterns were found in neonatal cartilage from control and patient samples. We also found that COL1A1 (Collagen I), a marker of osteogenic differentiation, was significantly (P<0.05) up-regulated at the mRNA level in TRPV4-iPSCs when compared with the control, and confirmed at the protein level. Collagen I expression in the TRPV4 model also may correlate with abnormal staining patterns seen in patient tissues. This study demonstrates that an iPSC model can recapitulate normal chondrogenesis and that mutant TRPV4-iPSCs reflect molecular evidence of aberrant chondrogenic developmental processes, which could be used to design therapeutic approaches for disorders of cartilage.
authors.affiliation: 1 Department of Biomedical Sciences, Cedars-Sinai Medical Center , Los Angeles, California.
authors.forename: Biagio
authors.initials: B
authors.lastname: Saitta
authors.forename: Jenna
authors.initials: J
authors.lastname: Passarini
authors.forename: Dhruv
authors.initials: D
authors.lastname: Sareen
authors.forename: Loren
authors.initials: L
authors.lastname: Ornelas
authors.forename: Anais
authors.initials: A
authors.lastname: Sahabian
authors.forename: Shilpa
authors.initials: S
authors.lastname: Argade
authors.forename: Deborah
authors.initials: D
authors.lastname: Krakow
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Cohn
authors.forename: Clive N
authors.initials: CN
authors.lastname: Svendsen
authors.forename: David L
authors.initials: DL
authors.lastname: Rimoin
mesh_terms: D001483:Base Sequence; D015415:Biomarkers / Q000378:metabolism; D055396:Bone Morphogenetic Protein 2 / Q000502:physiology*; D002454:Cell Differentiation; D002478:Cells, Cultured; D020219:Chondrogenesis; D024042:Collagen Type I / Q000235:genetics* / Q000378:metabolism; D000090602:Collagen Type I, alpha 1 Chain; D004252:DNA Mutational Analysis; D004392:Dwarfism / Q000235:genetics / Q000473:pathology; D015870:Gene Expression; D005786:Gene Expression Regulation; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000378:metabolism* / Q000502:physiology; D020125:Mutation, Missense; D010009:Osteochondrodysplasias / Q000235:genetics / Q000473:pathology; D050916:TRPV Cation Channels / Q000235:genetics; D053773:Transforming Growth Factor beta1 / Q000502:physiology*
chemical_list: C525718:BMP2 protein, human; D015415:Biomarkers; D055396:Bone Morphogenetic Protein 2; D024042:Collagen Type I; D000090602:Collagen Type I, alpha 1 Chain; C508960:TGFB1 protein, human; D050916:TRPV Cation Channels; C416986:TRPV4 protein, human; D053773:Transforming Growth Factor beta1